AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04724915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Total Knee Arthroplasty
Description: People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
Study NCT03292068 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acupuncture, acupressure
Description: Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care.
Study NCT03292068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Timbal diet
Description: Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
Study NCT03292068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extended telephone counseling
Description: Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
Study NCT00882323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine, Thymoglobulin
Description: cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)
Study NCT02067936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A propofol + remifentanil
Description: Predicted TOL90% according to Bouillon model
Study NCT02067936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B propofol + remifentanil
Description: TOL 90% according to the Bouillon interaction model
Study NCT02067936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C propofol + remifentanil
Description: TOL 90% according to the Bouillon interaction model
Study NCT02067936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group D propofol + remifentanil
Description: TOL 90% according to the Bouillon interaction model
Study NCT03305770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verofilcon A contact lenses
Description: Daily disposable soft contact lenses
Study NCT03305770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A contact lenses
Description: Daily disposable soft contact lenses
Study NCT01067144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
Study NCT01067144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam (active control)
Description: 0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
Study NCT01067144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (inactive)
Description: 2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
Study NCT01444885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
Study NCT01026441 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vela100 (Aesthetic)
Description: 6 treatments once a week
Study NCT02267122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ionic silver-containing dressing
Description: After placing the staples, a ionic silver-containing dressing was placed covering the wound
Study NCT02267122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment application
Description: After placing the staples, Mupirocin ointment application over the wound was performed
Study NCT03778788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App group
Description: Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
Study NCT00287716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: 1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study NCT00287716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study NCT00924248 — intervention group
Intervention type: DRUG
Intervention: Gadoxetic acid disodium (Primovist, BAY86-4873)
Description: Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
Study NCT00982826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: See Arms information for a detailed description.
Study NCT00982826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arms information for a detailed description.
Study NCT03472326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9131
Description: Tablet(s) administered orally once daily
Study NCT03472326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: Tablet(s) administered orally once daily
Study NCT03472326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet(s) administered orally once daily
Study NCT03472326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
Study NCT03472326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Tablet(s) administered orally once daily
Study NCT03472326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Tablet(s) administered orally once daily
Study NCT03374787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fusion Sound Processor
Description: Sound Processor
Study NCT00745537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repeated mood measures and phone depression care management
Description: The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
Study NCT02951078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium Laser en Bloc Resection of bladder tumor
Study NCT02951078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical transurethral resection of bladder tumor
Study NCT03670563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short foot exercise protocol
Description: Exercises that target intrinsic foot muscles
Study NCT03670563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short foot exercise plus NMES
Description: Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
Study NCT04007016 — intervention group
Intervention type: PROCEDURE
Intervention: a new osteotomy from the inner L shaped iliac osteotomy
Description: There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL
Study NCT01124279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: Single dose administration of AMG 853 in tablet form to healthy adult subjects
Study NCT02357017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NaCl tablets
Study NCT03778788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet group
Description: The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
Study NCT03778788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
Study NCT00901459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS Condition
Description: Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
Study NCT00901459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Location Control Condition
Description: Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
Study NCT00901459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Frequency Control Condition
Description: High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
Study NCT02543918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered by SQ injection
Study NCT01285804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cuffed ETT
Description: Kimberly Clark
Study NCT01285804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncuffed ETT
Description: Kimberly Clark
Study NCT02543918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Boostrix®
Description: Administered by IM injection
Study NCT02543918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: Administered by IM injection
Study NCT02543918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pneumovax®23
Description: Administered by IM injection
Study NCT02543918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumovax®23
Description: Administered by IM injection
Study NCT03557775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Description: IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
Study NCT03557775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Description: EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
Study NCT03903419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.
Description: This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI).
Study NCT03419754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose
Study NCT00610532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin
Description: intravenous phenytoin (15 mg/kg) single dose
Study NCT00610532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin and probenecid
Description: intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
Study NCT04689087 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTFields
Description: For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
Study NCT03950284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate loading with all on four technique in FFF
Description: All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
Study NCT02306356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Study NCT03419754 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fidgetting
Description: low intensity physical activity (fidgetting)
Study NCT03419754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fidgetting
Description: low intensity physical activity (fidgetting)
Study NCT02618876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine plus Bupivacaine
Description: Addition of caudal Nalbuphine to the standard Bupivacaine
Study NCT02618876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Caudal Bupivacaine is the standard of care will be considered as a control
Study NCT00422162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: 60 mg once or twice a day, by mouth
Study NCT00422162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule by mouth
Study NCT03256305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized rTMS+drug treatment
Description: High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
Study NCT03256305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rTMS +drug treatment
Description: Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
Study NCT01526486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videoscopic procedure
Description: Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
Study NCT01526486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open, traditional approach
Description: Open surgical procedure, with sartorius muscle transfer.
Study NCT04508829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR monoclonal antibody
Description: The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
Study NCT01630239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser ablation
Description: Laser ablation of hepatic tumors
Study NCT03370094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Audio-video-streaming of suspected stroke symptoms and signs
Description: The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
Study NCT01429168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: One 60-mg tablet orally daily
Study NCT03557775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Exercises
Description: Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
Study NCT03557775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Exercises
Description: Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
Study NCT02270021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Mobile Application (ProvAPP)
Description: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
Study NCT02270021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProvAPP + Patient Educational Tool (Tab)
Description: Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
Study NCT04179929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pediatric-type of chemotherapy
Description: Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
Study NCT04179929 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic HSCT
Description: allogeneic HSCT
Study NCT01203982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5mg/day for one year
Study NCT01203982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 40mg/day for one year
Study NCT00062829 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Driving: Program for parents
Description: A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
Study NCT03961932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study NCT01429168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for etoricoxib
Description: One 60-mg tablet orally daily
Study NCT03349203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
Study NCT04115488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusions
Description: Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses